Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 13:11:84-89.
doi: 10.1016/j.jdcr.2021.03.015. eCollection 2021 May.

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series

Ander Mayor Ibarguren  1 , Espinosa Arranz Enrique  2 , Peiteado Lopez Diana  3 , Custodio Ana  2 , Herranz Pinto Pedro  1
Affiliations
Case Reports

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series

Ander Mayor Ibarguren et al. JAAD Case Rep. .
No abstract available

Keywords: BSA, body surface area; ICI, immune checkpoint inhibitor; PASI, psoriasis area severity index; PD-1, programmed cell death protein 1; PDE-4 inhibitors; PDL-1, programmed death-ligand 1; PFS, progression free survival; PGA, physician's global assessment; anti-pd1; apremilast; immune checkpoint inhibitors; immune-induced psoriasis; immune-related adverse events; irAE, immune-related adverse events; nivolumab; pSA, psoriatic arthritis; psoriasis; supportive dermato-oncology.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Fig 1
Fig 1
Patient 1. A, Psoriatic plaques covering the right palm. B, Response to apremilast 30 mg twice daily.
Fig 2
Fig 2
Patient 2. A, Severe psoriatic plaques covering the patient's axillary fold. B, Response to apremilast 30 mg twice daily.
Fig 3
Fig 3
Patient 3. A, Severe inverse psoriasis. B, Response to apremilast 30 mg twice daily.
See this image and copyright information in PMC

Comment in

References

    1. Topalian S.L., Hodi F.S., Brahmer J.R. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. - PMC - PubMed
    1. Sibaud V., Meyer N., Lamant L., Vigarios E., Mazieres J., Delord J.P. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–263. - PubMed
    1. Matsumura N., Ohtsuka M., Kikuchi N., Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol. 2016;96(2):259–260. - PubMed
    1. Bonigen J., Raynaud-Donzel C., Hureaux J. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254–e257. - PubMed
    1. Voudouri D., Nikolaou V., Laschos K. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407–412. - PubMed

Publication types